培美曲塞联合顺铂治疗晚期复治性非小细胞肺癌90例临床观察  

Pemetrexed Concomitant Cisplatin Treatment of Advanced Non-Small Cell Lung Cancer of 90 Patients with Clinical Observation

作　　者：乐晓燕 

机构地区：[1]四川省成都市温江区人民医院肿瘤科,成都611100

出　　处：《中国医药导刊》2013年第7期1241-1242,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨培美曲塞联合顺铂治疗晚期复治性非小细胞肺癌(NSCLC)的临床效果。方法:对本院90例晚期复治性NSCLC患者均采用培美曲塞联合顺铂治疗。结果:90例患者经培美曲塞联合顺铂治疗的总有效率为30.00%,临床获益率为81.11%。随访5年,1年生存率为58.89%,3年生存率为28.89%、5年生存率为11.11%。毒副反应发生率最高的为发生白细胞降低71例(78.88%)明显高于其他毒副反应,差别有统计学意义(p<0.05),其次为恶心呕吐(56.67%)。经对症处理后,均毒副反应均改善,均未影响继续化疗。结论:对于一线治疗失败的晚期NSCLC患者来说,采用培美曲塞与顺铂联合化疗方案是理想的治疗方法之一。Objective： To study the pemetrexed concomitant cisplatin sex treatment of advanced non-small cell lung cancer（NSCLC） clinical effect.Methods： The 90 cases of patients with NSCLC sex late treat all use pemetrexed combined cisplatin treatment.Results： 90 cases of patients cured by the pemetrexed combined cisplatin treatment of the total effective rate was 30.00%,clinical benefit rate was 81.11%.Followed for 5 years,1-year survival was 58.89%,the 3 year survival rate 28.89% and 11.11% at 5 years.One of the highest rates of adverse reaction to occur leucocyte reduce 71 cases（78.88%） than the other side reaction,the difference was statistically significant（p ＆lt; 0.05）,followed by nausea and vomiting（56.67%）.The symptomatic treatment,all side reaction are improved,all did not influence continue chemotherapy.Conclusion： For the first line therapy for patients with advanced NSCLC failure,the pemetrexed and cisplatin combination chemotherapy regimens is one of the ideal treatment.

关 键 词：培美曲塞 顺铂 复治性 NSCLC 晚期 

分 类 号：R734.2[医药卫生—肿瘤]